Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 98478962 | 9847896 | 2 | F | 20130321 | 20130724 | 20130724 | PER | PHEH2013US002410 | NOVARTIS | 87.00 | YR | F | N | 0.00000 | 20130531 | N | CN | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 98478962 | 9847896 | 1 | PS | AFINITOR (RAD) UNKNOWN | 1 | ORAL | F009 | 203985 | 5 | MG | QD | ||||||||
| 98478962 | 9847896 | 2 | C | ARICEPT (DONEPEZIL HYDROCHLORIDE) | 1 | 0 | |||||||||||||
| 98478962 | 9847896 | 3 | C | AROMASIN (EXEMESTANE) | 1 | 0 | |||||||||||||
| 98478962 | 9847896 | 5 | C | ZOMETA (ZOLEDRONIC ACID) | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 98478962 | 9847896 | 1 | Breast cancer stage IV |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 98478962 | 9847896 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 98478962 | 9847896 | Breast cancer | |
| 98478962 | 9847896 | Malignant neoplasm progression | |
| 98478962 | 9847896 | Metastases to adrenals | |
| 98478962 | 9847896 | Metastases to bone | |
| 98478962 | 9847896 | Metastases to spine | |
| 98478962 | 9847896 | Neoplasm |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | CASEID | RPSR COD |
|---|---|---|
| 98478962 | 9847896 | CSM |
Therapies reported
| no results found |